MRI fluid-dynamics measure tracks Alzheimer’s biomarkers in ADNI analysis

What happened

The August 17 issue of *Neuroscience* carries an analysis of 407 Alzheimer’s Disease Neuroimaging Initiative participants that connects a diffusion-MRI measure called DTI-ALPS with several blood and imaging biomarkers across the Alzheimer’s disease continuum.

The mean DTI-ALPS index declined from cognitively healthy participants to those with Alzheimer’s disease. Lower values were also associated with greater tau accumulation on positron emission tomography in brain regions corresponding to multiple Braak stages. The pattern is potentially useful for research into how fluid movement and tissue changes relate to neurodegeneration, but the index remains an indirect and biologically nonspecific measurement.

This was an observational biomarker analysis, not a diagnostic-accuracy study or clinical trial. It cannot establish that impaired brain clearance caused Alzheimer’s pathology, that changing fluid dynamics would alter disease progression, or that the index can guide care for an individual patient.

What DTI-ALPS measures

Diffusion Tensor Image Analysis Along the Perivascular Space, abbreviated DTI-ALPS, uses diffusion-weighted MRI to quantify the directional movement of water in selected white-matter regions near presumed perivascular spaces. Researchers have proposed it as a noninvasive proxy for aspects of glymphatic activity—the exchange of cerebrospinal and interstitial fluid thought to contribute to waste removal from the brain.

“Proxy” is the important word. DTI-ALPS does not watch amyloid or tau being cleared, measure fluid flow directly, or capture the entire brain’s waste-removal system. Its signal may also reflect white-matter structure, vascular changes, inflammation, edema, fiber orientation and other age- or disease-related processes.

A recent systematic review identified substantial differences among studies in MRI acquisition, region-of-interest placement and image-processing methods. A separate population-based analysis of 2,715 participants concluded that the biological source of the DTI-ALPS signal remains unclear and found stronger evidence for an association with vascular dysfunction than for a specific measure of glymphatic clearance.

How the new analysis was designed

The investigators used data from ADNI, a longitudinal, multisite public-private research program supported by the National Institute on Aging. ADNI follows cognitively normal adults and people with mild cognitive impairment or Alzheimer’s disease while collecting clinical, genetic, fluid-biomarker and neuroimaging data.

For the new paper, researchers calculated DTI-ALPS indices and tested their relationships with plasma biomarkers and tau-PET burden. Regression models adjusted for age, sex, education, APOE ε4 status and mean diffusivity, a broader MRI measure that can reflect tissue microstructure.

The associations varied by clinical group. Among cognitively healthy participants, the mean DTI-ALPS index was associated with plasma phosphorylated tau 217 and amyloid-β40. In participants with mild cognitive impairment, selected index values were associated with amyloid-β42, neurofilament light and glial fibrillary acidic protein. Across the full sample, a lower mean index was associated with greater tau-PET burden in regions corresponding to Braak stages I through V.

That subgroup-specific pattern is scientifically interesting but complicates interpretation. It does not establish a single, consistent biomarker relationship across the disease continuum, and the handling of multiple statistical comparisons warrants close review in the full paper.

What the evidence means

The study adds multimodal evidence that DTI-ALPS captures brain changes relevant to Alzheimer’s research. Its use of an established cohort and adjustment for several important covariates strengthen the analysis. Combining diffusion MRI, blood markers and tau PET also provides a richer test than comparing the index with diagnosis alone.

The limitations remain substantial. The analysis reports associations rather than causal direction, relies on a selected research cohort, and does not show that DTI-ALPS improves diagnosis or prognosis beyond established assessments. It also cannot separate glymphatic activity from vascular and white-matter contributors to the diffusion signal.

The practical conclusion is therefore narrow: DTI-ALPS may be a useful research marker of Alzheimer-related brain changes, but it is not yet a validated clinical measure of glymphatic function. Longitudinal, multicenter studies with standardized imaging pipelines and direct physiological validation are needed before the index can be interpreted as more than an exploratory biomarker.